Health Condition 1: J069- Acute upper respiratory infection,unspecified
Conditions
Interventions
Intervention1: Kuka Cough Lozenges: Group A: Kuka Cough Lozenges (Tulsi mint)
Group B: Kuka Cough lozenges (Tulsi ginger)
Group C: Kuka Cough Lozenges (Tulsi Lemon)
Group D: Kuka Cough Lozenges (Tulsi
Sponsors
Multani Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Males and females with a history of acute cough due to any cause except those listed in exclusion criteria. 2. Throat irritation for 3. Patients having a cough score of 0, 1 or 2 during day time (as per Day Time Cough Scale described under end points) 4. Patients willing and able to provide signed ICF prior to study
Exclusion criteria
Exclusion criteria: 1. Participants with a history of acute lower respiratory tract infections such as pneumonia, bronchitis whooping cough, chronic obstructive pulmonary disease/asthma, tuberculosis, systemic bacterial infections for which specific drug therapy will be required; 2. Any underlying lung pathology such as lung abscess or cystic fibrosis 3. Individuals with a history of myocardial infarction within 4 weeks prior to enrollment; 4. Individuals with a history of Parkinsonâ??s disease and who were on monoamine oxidase inhibitors. 5. Individuals with any psychiatric illness which may impair the ability to provide written ICF. 6. Individuals participating in any other clinical trial. 7. Pregnant or lactating females. 8. Those who are under study treatment or any other condition due to which individuals are deemed unsuitable by the investigator for reason(s) not specifically stated in the exclusion criteria 9. Alcohol, smoke, and drug abusers will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in day/night time cough scales and throat irritation will be evaluated over a period of 3 days from baseline on verbal category descriptive (VCD) scale scoresTimepoint: 8 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to relief from cough and throat irritation for all the first morning doses, duration of relief from symptoms for all first morning doses, drowsiness, and Physicianâ??s Global Assessment of efficacy evaluated at visit 4 in both the treatment groups on VCD scalesTimepoint: 8 Days | — |
Countries
India
Contacts
Public ContactDr Rashmi Mutha
Multani Pharmaceutical Ltd
Outcome results
None listed